VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.

​

​

 

 

 

Aiming to submit NDA in 2020-2021.

VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.

​

​

 

 

 

Aiming to submit NDA in 2020-2021.

VTS-K: Ketamine + VTS Aspirin for Postoperative Pain

VTS-K: Ketamine + VTS Aspirin for Postoperative Pain

Vitalis
  • About Us

  • VTS-Platform

  • What is Flush?

  • Pipeline

    • Multiple Sclerosis
    • Post-op Pain
    • Dyslipidemia
  • Media

  • Contact Us

  • More

    Use tab to navigate through the menu items.

    Media

    News
    Press Releases
    Events

    Vitalis to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

    H.C. Wainwright

    Webcast Access Link

    Wednesday, September 16, 2020 at 3PM

    © 2019 Vitalis, LLC

    All Rights Reserved.

    New York, NY

    admin@vitalispharma.com

     

    ​

    Cookie Policy

    Terms of Use

    Privacy Policy

    Media